-
Something wrong with this record ?
Neuropeptide Y as a risk factor for cardiorenal disease and cognitive dysfunction in chronic kidney disease: translational opportunities and challenges
C. Zoccali, A. Ortiz, IA. Blumbyte, S. Rudolf, AG. Beck-Sickinger, J. Malyszko, G. Spasovski, S. Carriazo, D. Viggiano, J. Kurganaite, V. Sarkeviciene, D. Rastenyte, A. Figurek, M. Rroji, C. Mayer, M. Arici, G. Martino, G. Tedeschi, A. Bruchfeld,...
Language English Country Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
Free Medical Journals
from 1996 to 1 year ago
Open Access Digital Library
from 1996-01-01
PubMed
34724060
DOI
10.1093/ndt/gfab284
Knihovny.cz E-resources
- MeSH
- Renal Insufficiency, Chronic * complications therapy MeSH
- Renal Dialysis MeSH
- Cognitive Dysfunction * etiology MeSH
- Humans MeSH
- Neuropeptide Y MeSH
- Receptors, Neuropeptide Y MeSH
- Hypertension, Renal * MeSH
- Risk Factors MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Neuropeptide Y (NPY) is a 36-amino-acid peptide member of a family also including peptide YY and pancreatic polypeptide, which are all ligands to Gi/Go coupled receptors. NPY regulates several fundamental biologic functions including appetite/satiety, sex and reproduction, learning and memory, cardiovascular and renal function and immune functions. The mesenteric circulation is a major source of NPY in the blood in man and this peptide is considered a key regulator of gut-brain cross talk. A progressive increase in circulating NPY accompanies the progression of chronic kidney disease (CKD) toward kidney failure and NPY robustly predicts cardiovascular events in this population. Furthermore, NPY is suspected as a possible player in accelerated cognitive function decline and dementia in patients with CKD and in dialysis patients. In theory, interfering with the NPY system has relevant potential for the treatment of diverse diseases from cardiovascular and renal diseases to diseases of the central nervous system. Pharmaceutical formulations for effective drug delivery and cost, as well as the complexity of diseases potentially addressable by NPY/NPY antagonists, have been a problem until now. This in part explains the slow progress of knowledge about the NPY system in the clinical arena. There is now renewed research interest in the NPY system in psychopharmacology and in pharmacology in general and new studies and a new breed of clinical trials may eventually bring the expected benefits in human health with drugs interfering with this system.
Associazione Ipertensione Nefrologia Trapianto Renale Reggio Cal Italy
Biogem Scarl Ariano Irpino Italy
c o CNR IFC Ospedali Riuniti Reggio Calabria Italy
Department of Nephrology Dialysis and Internal Medicine Warsaw Medical University Warsaw Poland
Department of Nephrology Faculty of Medicine University of Medicine Tirana Tirana Albania
Department of Nephrology Hacettepe University School of Medicine Ankara Turkey
Department of Nephrology University 'Sts Cyril and Methodius' Skopje MK Republic of Macedonia
Department of Translational Medical Sciences University of Campania 'Luigi Vanvitelli' Naples Italy
Faculty of Life Sciences Institute of Biochemistry Leipzig University Leipzig Germany
Health and Bioresources Biomedical Systems Austrian Institute of Technology Vienna Austria
Institute of Anatomy University of Zurich Zurich Switzerland
Nephrology and Transplantation Unit Grande Ospedale Metropolitano and CNR IFC Reggio Calabria Italy
Nephrology Department Lithuanian University of Health Sciences Kaunas Lithuania
Neurology Department Lithuanian University of Health Sciences Kaunas Lithuania
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22011630
- 003
- CZ-PrNML
- 005
- 20220506130542.0
- 007
- ta
- 008
- 220425s2021 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1093/ndt/gfab284 $2 doi
- 035 __
- $a (PubMed)34724060
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Zoccali, Carmine $u Renal Research Institute, New York, NY, USA $u Associazione Ipertensione Nefrologia Trapianto Renale Reggio Cal, Italy $u c/o CNR-IFC, Ospedali Riuniti, Reggio Calabria, Italy $1 https://orcid.org/0000000266161996
- 245 10
- $a Neuropeptide Y as a risk factor for cardiorenal disease and cognitive dysfunction in chronic kidney disease: translational opportunities and challenges / $c C. Zoccali, A. Ortiz, IA. Blumbyte, S. Rudolf, AG. Beck-Sickinger, J. Malyszko, G. Spasovski, S. Carriazo, D. Viggiano, J. Kurganaite, V. Sarkeviciene, D. Rastenyte, A. Figurek, M. Rroji, C. Mayer, M. Arici, G. Martino, G. Tedeschi, A. Bruchfeld, B. Spoto, I. Rychlik, A. Wiecek, M. Okusa, G. Remuzzi, F. Mallamaci, CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target)
- 520 9_
- $a Neuropeptide Y (NPY) is a 36-amino-acid peptide member of a family also including peptide YY and pancreatic polypeptide, which are all ligands to Gi/Go coupled receptors. NPY regulates several fundamental biologic functions including appetite/satiety, sex and reproduction, learning and memory, cardiovascular and renal function and immune functions. The mesenteric circulation is a major source of NPY in the blood in man and this peptide is considered a key regulator of gut-brain cross talk. A progressive increase in circulating NPY accompanies the progression of chronic kidney disease (CKD) toward kidney failure and NPY robustly predicts cardiovascular events in this population. Furthermore, NPY is suspected as a possible player in accelerated cognitive function decline and dementia in patients with CKD and in dialysis patients. In theory, interfering with the NPY system has relevant potential for the treatment of diverse diseases from cardiovascular and renal diseases to diseases of the central nervous system. Pharmaceutical formulations for effective drug delivery and cost, as well as the complexity of diseases potentially addressable by NPY/NPY antagonists, have been a problem until now. This in part explains the slow progress of knowledge about the NPY system in the clinical arena. There is now renewed research interest in the NPY system in psychopharmacology and in pharmacology in general and new studies and a new breed of clinical trials may eventually bring the expected benefits in human health with drugs interfering with this system.
- 650 12
- $a kognitivní dysfunkce $x etiologie $7 D060825
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a renální hypertenze $7 D006977
- 650 _2
- $a neuropeptid Y $7 D009478
- 650 _2
- $a receptory neuropeptidu Y $7 D017476
- 650 _2
- $a dialýza ledvin $7 D006435
- 650 12
- $a chronická renální insuficience $x komplikace $x terapie $7 D051436
- 650 _2
- $a rizikové faktory $7 D012307
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Ortiz, Alberto $u Faculty of Life Sciences, Institute of Biochemistry, Leipzig University, Leipzig, Germany $1 https://orcid.org/0000000298059523
- 700 1_
- $a Blumbyte, Inga Arune $u Nephrology Department, Lithuanian University of Health Sciences, Kaunas, Lithuania
- 700 1_
- $a Rudolf, Sarina $u Faculty of Life Sciences, Institute of Biochemistry, Leipzig University, Leipzig, Germany
- 700 1_
- $a Beck-Sickinger, Annette G $u Faculty of Life Sciences, Institute of Biochemistry, Leipzig University, Leipzig, Germany $1 https://orcid.org/0000000345608020
- 700 1_
- $a Malyszko, Jolanta $u Department of Nephrology, Dialysis and Internal Medicine, Warsaw Medical University, Warsaw, Poland
- 700 1_
- $a Spasovski, Goce $u Department of Nephrology, University 'Sts. Cyril and Methodius', Skopje, MK, Republic of Macedonia
- 700 1_
- $a Carriazo, Sol $u Faculty of Life Sciences, Institute of Biochemistry, Leipzig University, Leipzig, Germany $1 https://orcid.org/0000000266975279
- 700 1_
- $a Viggiano, Davide $u Department of Translational Medical Sciences, University of Campania 'Luigi Vanvitelli', Naples, Italy $u Biogem Scarl, Ariano Irpino, Italy
- 700 1_
- $a Kurganaite, Justina $u Nephrology Department, Lithuanian University of Health Sciences, Kaunas, Lithuania
- 700 1_
- $a Sarkeviciene, Vaiva $u Nephrology Department, Lithuanian University of Health Sciences, Kaunas, Lithuania
- 700 1_
- $a Rastenyte, Daiva $u Neurology Department, Lithuanian University of Health Sciences, Kaunas, Lithuania
- 700 1_
- $a Figurek, Andreja $u Institute of Anatomy, University of Zurich, Zurich, Switzerland
- 700 1_
- $a Rroji, Merita $u Department of Nephrology, Faculty of Medicine, University of Medicine Tirana, Tirana, Albania
- 700 1_
- $a Mayer, Christopher $u Health and Bioresources, Biomedical Systems, Austrian Institute of Technology, Vienna, Austria
- 700 1_
- $a Arici, Mustapha $u Department of Nephrology, Hacettepe University School of Medicine, Ankara, Turkey
- 700 1_
- $a Martino, Gianvito $u Neurology Department, San Raffaele Scientific Institute and Vita-Salute University San Raffaele, Milan, Italy $1 https://orcid.org/0000000312959131
- 700 1_
- $a Tedeschi, Gioacchino $u Department of Advanced Medical and Surgical Sciences, and 3T-MRI Research Center, University of Campania 'Luigi Vanvitelli', Naples, Italy
- 700 1_
- $a Bruchfeld, Annette $u Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden and Department of Renal Medicine, CLINTEC Karolinska Institutet, Stockholm, Sweden $1 https://orcid.org/0000000297529941
- 700 1_
- $a Spoto, Belinda $u CNR-IFC, Reggio Calabria, Italy
- 700 1_
- $a Rychlik, Ivan $u Third Faculty of Medicine, Department of Medicine, Charles University and Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic
- 700 1_
- $a Wiecek, Andrzej $u Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia in Katowice, Katowice, Poland
- 700 1_
- $a Okusa, Mark $u Division of Nephrology and Center for Immunity, Inflammation, and Regenerative Medicine, University of Virginia, Charlottesville, VA, USA
- 700 1_
- $a Remuzzi, Giuseppe $u Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Clinical Research Center for Rare Diseases, Aldo e Cele Daccò Bergamo, Italy
- 700 1_
- $a Mallamaci, Francesca $u Nephrology and Transplantation Unit, Grande Ospedale Metropolitano and CNR-IFC, Reggio Calabria, Italy
- 710 2_
- $a CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target)
- 773 0_
- $w MED00010288 $t Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association $x 1460-2385 $g Roč. 37, Suppl 2 (2021), s. ii14-ii23
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34724060 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220506130534 $b ABA008
- 999 __
- $a ok $b bmc $g 1789305 $s 1162828
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 37 $c Suppl 2 $d ii14-ii23 $e 20211228 $i 1460-2385 $m Nephrology, dialysis, transplantation $n Nephrol Dial Transplant $x MED00010288
- LZP __
- $a Pubmed-20220425
